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Open access under CC BY licG protein-coupled receptors (GPCRs) are the largest family of transmembrane receptors in the mamma-
lian genome. They are activated by a multitude of different ligands that elicit rapid intracellular responses
to regulate cell function. Unsurprisingly, a large proportion of therapeutic agents target these receptors.
The paraventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus are important
mediators in homeostatic control. Many modulators of PVN/SON activity, including neurotransmitters
and hormones act via GPCRs – in fact over 100 non-chemosensory GPCRs have been detected in either
the PVN or SON. This review provides a comprehensive summary of the expression of GPCRs within
the PVN/SON, including data from recent transcriptomic studies that potentially expand the repertoire
of GPCRs that may have functional roles in these hypothalamic nuclei. We also present some aspects
of the regulation and known roles of GPCRs in PVN/SON, which are likely complemented by the activity
of ‘orphan’ GPCRs.
 2011 Elsevier Inc. Open access under CC BY license.1. Introduction
The hypothalamo-neurohypophysial system (HNS) responds to
dehydration by increasing vasopressin (VP) and oxytocin (OT) gene
transcription and translation, and releasing large amounts of VP
and OT into the systemic circulation. Similarly, acute and chronic
stress, pregnancy, and lactation are all associated with phenotypic
changes in the paraventricular (PVN) and/or supraoptic (SON)
nuclei of the hypothalamus that include elevations in VP, OT
and/or corticotropin-releasing factor (CRF) gene expression
[2,42]. Alterations in the pattern and/or level of modulating inputs
(e.g., receptor-driven signals) that impinge on the PVN and SON
have important functional implications in the control of the HNS
and the hypothalamic–pituitary–adrenal (HPA) axis response to
stress. The activity of such inputs may drive changes in the
PVN/SON VP and OT signature associated with a number of
neuroendocrinological disturbances [314], and contribute to the
dysregulation of the HPA axis implicated in many conditions
including the classical psychosomatic disorders, cardiovascular
disease, diabetes and affective disorders such as depression.
Receptor function in the PVN/SON may also be altered in immuno-ense.logically-related disturbances such as immunosuppression and
autoimmune, allergic and inﬂammatory states [48,262].
By virtue of their expression in the PVN and SON, many recep-
tors are key targets for regulating hypothalamic–HNS and -HPA
axis activity. There are four major classes of receptors in the central
nervous system (CNS) – (1) the ionotropic receptors such as the
excitatory glutamate (e.g., N-methyl-D-aspartate (NMDA)) or
inhibitory GABAA receptors that create a membrane pore to allow
the ﬂow of ions, and have a very rapid response time; (2) receptor
tyrosine kinases such as tyrosine kinase receptor type B (TrkB) and
the epidermal growth factor receptor (EGFR), which upon stimula-
tion activate intracellular signaling networks like the mitogen-
activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) pathway; (3) nuclear receptors including glucocorti-
coid, sex steroid and thyroid hormone receptors that regulate
transcriptional activation; and (4) G protein-coupled receptors
(GPCRs), or seven transmembrane (TM) receptors, occasionally
termed heptahelical or ‘serpentine’ receptors. GPCRs constitute
the largest superfamily of transmembrane signaling molecules,
estimated to comprise about 1900 members (not including
pseudogenes) in the rat and mouse genomes, and at least 800
members in the human genome [99]. The proportion of one-
to-one GPCR orthologues is approximately 60% between rats and
humans, primarily due to divergence in chemosensory receptors
that are activated by sensory signals of external origin such as
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60% of all GPCRs in the rat and mouse genome and 50% in the hu-
man genome [99]. Most other GPCRs are activated by a diverse ar-
ray of endogenous, extracellular (and perhaps intracellular) signals
that include photons, biogenic amines, neuropeptides, amino acids,
ions, hormones, chemokines, lipid-derived mediators and prote-
ases. Upon ligand binding, GPCRs primarily transduce these signals
via the heterotrimeric G proteins into rapid intracellular responses
that regulate cell function (e.g., increases in protein kinase C (PKC)
and/or protein kinase A (PKA) activity, intracellular Ca2+ and cyclic
AMP (cAMP)). It is estimated that 80% of all known hormones and
neurotransmitters activate cellular signal transduction mecha-
nisms via GPCRs [21], and a substantial portion (estimates vary be-
tween 30% and 60%) of current pharmaceutical agents directly or
indirectly act on these receptors [130,205] – angiotensin II and
aminergic (adrenoceptor, dopamine, 5-hydroxytryptamine (5-
HT)) receptor subtypes feature as prominent drug targets [137].
There are still 120–130 non-chemosensory ‘orphan’ GPCRs for
which the corresponding ligands have not yet been identiﬁed
[99,111].
In this review we will highlight efforts to examine GPCR
expression and regulation in the rat PVN and SON by receptor
autoradiography (ARG), immunohistochemistry (IHC) and in situ
hybridization histochemistry (ISHH) methods in conjunction with
more recent transcriptomic approaches (e.g., DNA microarrays) to
present an overall estimate of the GPCR repertoire expressed in
the PVN and SON. We have collated data on all of the known
non-chemosensory GPCRs documented in the on-line International
Union of Basic and Clinical Pharmacology Committee on Receptor
Nomenclature and Drug Classiﬁcation database (NC-IUPHAR;
http://www.iuphar-db.org/) [111] including orphan GPCRs. These
data will be discussed in the context of the regulation and function
(and possible redundancy) of GPCRs in the PVN and SON as
revealed by current pharmacological/physiological approaches in
rats, the species in which the vast majority of studies on the HNS
and HPA axis have been conducted. With respect to GPCR localiza-
tion in the PVN and SON we have endeavored to cite as many of the
original reference sources as possible – we apologize in advance if
we have inadvertently omitted some citations. The architecture of
the PVN/SON, GPCR structure/function studies, and the function of
many neurotransmitters/neurohormones in the PVN and/or SON
have been extensively reviewed and we shall refer to these papers
throughout. In this review we shall use the GPCR subfamily
nomenclature (e.g., 5-HT1A; rather than rat gene name (e.g., Htr1a))
as per NC-IUPHAR recommendations [111].2. Anatomy and function of the rat PVN and SON
The hypothalamus is essential for maintaining homeostatic
equilibrium, integrating signals from other brain regions to regu-
late an assortment of functions including temperature regulation,
appetite and fertility. Within the hypothalamus the PVN and SON
are two of the most exhaustively studied nuclei and are fundamen-
tal in the control of ﬂuid homeostasis, lactation, cardiovascular reg-
ulation, feeding behavior, nociception, behavior and the response
to stress. The PVN is located either side of the third ventricle,
and can be subdivided into ﬁve parvocellular (pPVN) (periventric-
ular, anterior, medial, dorsal and lateral parts) and three magnocel-
lular (mPVN) (anterior, medial and posterior parts) divisions
[295,316]. The main neuronal populations in the mPVN and pPVN
subdivisions are intermingled with interneurons and supporting
cells such as glia. The SON straddles the lateral border of the optic
chiasm and contains a ‘homogeneous’ population of magnocellular
neurons [255]. The large magnocellular neurons in the PVN and
SON secrete mainly VP and OT as part of the HNS whereas thesmaller parvocellular neurons elaborate primarily CRF, VP and OT
as part of the HPA axis and/or regulate autonomic activity. Elegant,
detailed studies on the mapping of the spatial organization of
major neuroendocrine and non-neuroendocrine neurons in the
rat PVN have revealed that although neuroendocrine neuron
clusters display a unique distribution pattern, there is extensive
overlap between different phenotypes [295]. For instance, there
is some intermixing of magnocellular and parvocellular neurons
particularly at the mPVN/pPVN border [295], and isolated magno-
cellular cells in the pPVN have been noted [75]. Moreover, there is
evidence that the HNS and HPA axis may functionally overlap but
the extent of this interaction is not fully understood [75].
Magnocellular neurons of both the PVN and SON project via the
internal zone of the median eminence to the posterior pituitary,
and upon appropriate stimulation secrete VP and/or OT into the
peripheral blood. Magnocellular VP is released mainly in response
to dehydration, hypovolemia and hypotension, while magnocellu-
lar OT is primarily involved in the milk ejection reﬂex during lacta-
tion, and uterine contraction at the later stages of parturition
[98,255,265,311]. Parvocellular neurons project from the periven-
tricular, anterior, and medial (dorsal portion) parts of the PVN to
the external zone of the median eminence, and release their pep-
tides into the hypophysial portal system, a series of blood vessels
that bathe the anterior lobe of the pituitary. In response to stressful
stimuli, CRF and VP from the dorsomedial pPVN stimulate the
release of adrenocorticotropin releasing hormone (ACTH) from
the corticotrope cells of the anterior pituitary, which in turn
induces the secretion of cortisol (corticosterone (CORT) in rodents)
from the adrenal glands. CORT exerts a negative feedback action on
the pituitary, PVN and other brain regions such as the hippocam-
pus to restrict the dramatic initial release of ACTH and CORT [7].
OT can either potentiate or inhibit ACTH and/or CORT responses
by binding to the pituitary VP V1B receptor or by an action on
central OT receptors, respectively [273,354]. In addition, OT stimu-
lates the release of luteinising hormone from gonadotropes, and
prolactin from lactotropes in the anterior pituitary [98]. Other par-
vocellular neuroendocrine cells include those that express growth
hormone-releasing hormone (GHRH), somatostatin, dopamine and
thyrotropin-releasing hormone (TRH) [295]. Parvocellular neurons
from the dorsal, lateral, and medial (ventral portion) regions of the
PVN also project to other regions of the brain, in particular to the
brain stem and spinal cord [316]. Here the parvocellular neuro-
transmitters/neuropeptides modulate somatomotor-behavioral
and autonomic circuitry; for example, CRF axons terminate in
regions such as the locus coeruleus, where the peptide is reported
to interact with noradrenergic neurons [72,332], VP neurons
project to autonomic nuclei in the brainstem and spinal cord,
and are involved in cardiovascular control [20,259,300], while
parvocellular OT released in the hindbrain/spinal cord inﬂuences
nociception, gastric reﬂexes, cardiovascular responses, yawning
and penile erection [98,163,204,259]. Moreover, dendritically
released neuropeptides from magnocellular perikarya may act
locally or diffuse away from the PVN/SON, contributing to the
central OT and VP pool [204]. It has been proposed that centrally
released OT and VP from dendrites and/or parvocellular projections
modulates behavior e.g., maternal and afﬁliative behavior, sexual
behavior, and social recognition [107,204,309].
The PVN and SON are subject to regulation by many brain
regions including the hindbrain/brainstem, limbic regions, lamina
terminalis system, and other hypothalamic nuclei, and also from
chemicals/hormones such as estrogen and CORT that can pass
the blood brain barrier [63,114,223,298,316]. As such the PVN/
SON is modulated by a considerable array of neurotransmitters
and hormones. For example, neurons of the PVN/SON are im-
mersed in glutamatergic and GABAergic terminals that provide
major stimulatory and inhibitory tone, respectively. Input from
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serotonergic afferents from the ventral medulla, and catechol-
amine projections from the nucleus of the solitary tract and locus
coeruleus, all of which may co-express additional neurotransmit-
ters or neuropeptides [298,316,331]. The PVN and SON also receive
efferents from the subfornical organ, and those projecting to the
PVN have been shown to contain angiotensin II [82], while neuro-
peptide Y (NPY)- and pro-opiomelanocortin (POMC)-expressing
neurons projecting to the PVN from the arcuate nucleus [283]
are essential for the complex control of feeding behavior [285].
Further, parvocellular and magnocellular neurons of the PVN/
SON coexpress many neuroactive substances (e.g., CRF, galanin,
cholecystokinin, enkephalin, and vasoactive intestinal peptide
(VIP)) that may have a paracrine/autocrine action on PVN/SON
neurons [39,47]. Importantly, in response to various physiological
conditions the PVN and SON exhibit a considerable degree of mor-
phological (e.g., glial cell remodeling [115]) and functional plastic-
ity. This can manifest itself by changes in neuronal excitability
[84,322] that may be accompanied by enhanced co-expression ofopt
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Fig. 1. Schematic diagram representing the possible roles of GPCRs in modulating PVN
activity directly (substances such as neuropeptide Y and orexin A [153,154] that can pas
GPCRs in the circumventricular organs by humoral factors like cytokines, or neuropeptide
neurons projecting to the PVN/SON). (2) Local release of neurotransmitters from within
paracrine effects on PVN/SON neurons e.g., priming of OT neurons by dendritically releas
GnRH [335]) released from alternate (ventricular bordering) brain regions may reach th
Similarly, dendritically released OT and VP from PVN neurons may permeate into the cere
regions [335]. (3) GPCRs may modulate the activity of neurons that project away from th
perikarya within the PVN/SON and/or at the nerve terminals in different brain regions
GABAergic and glutamatergic) within the PVN/SON and/or neurons originating from o
brainstem), that synapse with PVN/SON soma, possibly regulating postsynaptic neurotran
GPCRs present in the external zone of the median eminence could modulate the secretion
the pituitary could have a direct effect on hormone release e.g., regulate VP/OT release fro
anterior lobe (7). PVN, paraventricular nucleus; SON, supraoptic nucleus; ME, median em
3 V, third ventricle.certain neuropeptides (e.g., VP in CRF pPVN neurons after stress
exposure [2,39]) and/or altered neuro-transmitter/peptide release
[42,202].
The deﬁned cytoarchitecture of the rat PVN and SON and the
features of the neurons contained within and projecting from these
nuclei (e.g., large size of magnocellular cells; accessibility to exper-
imental manipulation with reference to the SON in particular;
physiologically deﬁned outputs) make these brain regions excel-
lent models to investigate GPCR function. As shown in Fig. 1, GPCRs
can modulate PVN/SON activity at a number of levels.
3. Structure and function of GPCRs
In the CNS, GPCR ligands function mainly as slow neuromodu-
lators rather than the fast, small molecule neurotransmitters such
as glutamate and GABA acting on ionotropic receptors. Tradition-
ally GPCRs are regarded as plasma membrane-bound receptors,
although some are not highly expressed on the cell surface (e.g.,
human gonadotropin releasing hormone (GnRH) receptor [83]opt
AP
3
6
1
2
/SON activity. (1) Hormonal signals from peripheral blood may regulate PVN/SON
s through the blood brain barrier activating GPCRs), or indirectly (e.g., activation of
s such as angiotensin II [92] can regulate neurotransmitter/neuropeptide-expressing
PVN/SON (e.g., from dendrites) that act on GPCRs may have potential autocrine/
ed OT in parturition/lactation [204]. In addition, neurotransmitters (e.g., melatonin,
e PVN via the ventricular system, and act to regulate neuronal activity via GPCRs.
brospinal ﬂuid of the third ventricle and diffuse to, and act on, GPCRs in distant brain
e PVN/SON (e.g., parvocellular PVN projections to the hindbrain), acting directly on
. (4) GPCRs may be present on/or near the nerve terminals of interneurons (e.g.,
ther regions (e.g., alternate areas of the hypothalamus, hippocampus, amygdala,
smitter release or acting directly to stimulate/inhibit PVN/SON neuronal activity. (5)
of CRF/OT/VP from parvocellular neurons into the portal blood stream, and GPCRs in
m the neural lobe (6) and ACTH (amongst other neuroendocrine hormones) from the
inence; NL, neural lobe; IL, intermediate lobe; AP, anterior pituitary; opt, optic tract;
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evidence suggests that functional GPCRs may be found in intracel-
lular compartments such as the endoplasmic reticulum, golgi
apparatus, nuclear membrane and even inside the nucleus itself
[26,43,51,264,266]. The structure/function relationship of GPCRs
has been covered extensively and we refer the reader to a number
of excellent recent reviews (e.g., [59,128,274]). At a basic level all
GPCRs have a common structure of seven membrane-spanning do-
mains, ﬂanked by an extracellular amino terminus and an intracel-
lular carboxyl terminus. The transmembrane (TM) domains are
formed by seven hydrophobic a-helices linked by alternating
extracellular and intracellular loops. Much of what we know about
GPCR ligand-binding pockets and G protein-coupling domains
comes from site-directed mutagenesis and chimeric receptor stud-
ies assisted on occasions by computational modeling (e.g.,
[95,349,351]). In general, this large body of work has revealed that
the extracellular and TM domains are responsible for ligand bind-
ing, while intracellular domains dock and activate G proteins, and
anchor the receptor to the membrane. The intracellular domains
are also targets for post-translational modiﬁcation such as phos-
phorylation which play a critical role in GPCR ‘memory’ resulting
in reduced (desensitization) or augmented (sensitization) re-
sponses [90]. GPCR desensitization in response to agonist stimula-
tion is common to nearly all GPCRs, and typically involves GPCR
kinase (GRK)- or other kinase-induced phosphorylation of the acti-
vated GPCR, and recruitment of b-arrestins to uncouple the recep-
tor from its associated G protein, and targeting of the GPCR for
endocytosis by linking it to ‘adaptor’ molecules such as clathrin
[90,326]. The amino terminus invariably contains N-linked glyco-
sylation sites involved in intracellular receptor trafﬁcking, mem-
brane expression and ligand binding [350], and the carboxyl
terminus hosts sites for palmitoylation to facilitate interaction
with the membrane, and together with phosphorylation sites have
roles in receptor dimerization and internalization, and intracellular
signaling [134]. GPCRs can be grouped into four main classes based
on shared sequence motifs: (1) Class A (rhodopsin-like), the largest
GPCR class that includes the earliest GPCRs cloned (b2-adrenocep-
tor [69], acetylcholine M1 [170]) and the aminergic, olfactory and
majority of neuropeptide GPCRs; (2) Class B (secretin-like),
comprising calcitonin, glucagon, CRF and parathyroid hormone
receptors that have a characteristic long amino-terminus tail con-
taining three conserved disulﬁde bonds; (3) Class C (metabotropic
glutamate-like) with an amino terminus consisting of two lobe-like
structures that resemble that of a ‘venus ﬂytrap’ (e.g., metabotropic
glutamate, calcium-sensing, and GABAB receptors); and (4) Friz-
zled/Smoothened receptors, which are the sole members of the
fourth group. Frizzled receptors have a large amino terminus,
and are important in embryonic development and adult tissue
homeostasis, while Smoothened receptors contribute to the hedge-
hog signaling system, and are involved in embryogenesis and
tumorigenesis [111,246].
For many years the prototypical reference for GPCR organiza-
tion in the lipid bilayer has been based on rhodopsin and its
high-resolution X-ray crystallographic structure [248]. The suc-
cessful crystallography of hormone-binding GPCRs is a signiﬁcant
breakthrough in GPCR research that has required the recombinant
generation of high levels of GPCR protein, enhancing their stability
(e.g., using stabilizing ligands) and structural modiﬁcations to
encourage crystal formation. The structures of a number of Class
A GPCRs (e.g., b1- and b2-adrenoceptors [52,263]; adenosine A2A
receptor [142] and the minimally active conformation of opsin
(the ligand-free form of rhodopsin) [249]) have now been eluci-
dated, conﬁrming that essentially all Class A (and by extension
Classes B and C) GPCRs possess seven membrane-spanning helical
domains arranged in a bundle with a cytoplasmic eighth helix
immediately following TM7. One insight from the small numberof X-ray crystallography studies to date is that each subfamily of
GPCRs possesses its own unique mode of natural ligand binding
reﬂecting their unique structure. In the rat genome there are a total
of 356 non-chemosensory GPCRs of which 132 are classiﬁed as
orphans [111].
GPCRs are coupled to G proteins that are comprised of three
subunits: Ga, Gb and Gc. Stimulation from physiological, environ-
mental or experimental signals provokes a conformational change
in the receptor-7TM structure, catalyzing the replacement of GDP
for GTP on the Ga subunit. Subsequently, Ga detaches from Gbc
to create two separate components that can activate a multitude
of intracellular signaling pathways e.g., Ga may increase adenylyl
cyclase activity, whilst Gbc can independently act to stimulate
phospholipases and MAPK/ERKs, and activate ion channels. Het-
erotrimeric G proteins are encoded by a family of related genes
that comprises 21 Ga, 5 Gb and 12 Gc mammalian genes, giving
rise to a variety of G protein combinations [70]. They are catego-
rized into four main groups according to the structure and function
of the a subunit: Gas, Gaq/11, Gai, and Ga12/13 [246]. Gas typically
activates adenylate cyclases that catalyze the production of cAMP
from ATP, stimulating PKA activity. Gaq/11 couples to and activate
phospholipase Cb (PLCb), and increases intracellular Ca2+ and PKC
activity. Gai often inhibits adenylate cyclase activity, impeding
cAMP synthesis, as well as activating G protein-coupled potassium
channels. The remaining group of G proteins is the Ga12/13 family
that regulate the small G protein Rho through Rho-speciﬁc guanine
nucleotide exchange factors [254].
A typical feature of GPCR signaling is that by activating a
cascade of signal transduction mediators the signals can be ampli-
ﬁed. Cross-talk between GPCRs, or GPCRs and other proteins at
the cell surface (e.g., via oligomerization) and in the cytoplasm
(e.g., via convergent signaling pathways such as Gs/Gq/Gi and
receptor tyrosine kinase-activation of MAPK–ERKs) can modify
GPCR-mediated signaling. In addition, GPCRs vary in their speci-
ﬁcity for activating/coupling to the G protein subtypes with some
activating only one Ga subtype while others are more promiscu-
ous and couple to a number of Ga proteins to activate multiple
intracellular signaling cascades. The ability of GPCRs to activate
more than one class of G proteins can depend on receptor density,
the nature of the ligand (different responses to two ligands can
confer ‘functional selectivity’), tissue distribution, and on its local-
ization within specialized compartments of the plasma membrane
which may depend on whether the GPCR is active in a monomeric
or oligomeric form [158,219,355,371]. One facet of GPCR intracel-
lular signaling that should not be overlooked is that some GPCRs
can activate both G protein-dependent and G protein-independent
pathways. For example, angiotensin II AT1A receptor-triggered
transactivation of the EGFR, and b-arrestin-dependent and
-independent AT1A receptor internalization can take place inde-
pendently of G protein activation [81]. In addition, AT1A-mediated
activation of ERK features both Gq- and b-arrestin-dependent
pathways [181], while b2-adrenoceptor stimulation of the
MAPK–ERK pathway is Gs-coupled and Ga-independent/tyrosine
kinase Src-dependent at low and high concentrations of stimulat-
ing agonist, respectively [313]. Overall it is apparent that GPCRs
dynamically interact with numerous associated proteins as part
of a tightly regulated signaling network, and this interaction in
different tissues reﬂects the types of signaling components within
a given cell and the receptor’s physiological role.4. GPCR expression in the PVN and SON
Over 90% of non-chemosensory GPCRs are expressed in the
mouse brain with a large proportion (82% of those examined by
RT-PCR) expressed in the hypothalamus [334]. The proﬁles of the
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region-speciﬁc intracellular signaling component expression
(see Section 4.1 below), yield thousands of GPCR signaling
combinations for the modulation of physiological processes. Some
GPCRs even appear to be relatively conﬁned to the CNS, although it
is rare to ﬁnd evidence of CNS exclusivity if techniques such as
reverse-transcription (RT)-PCR or EST proﬁling (e.g., see http://
www.ncbi.nlm.nih.gov/UniGene/) are used.
After a ﬂourish of research in the 1980s/early 1990s localizing
GPCRs by receptor autoradiography (ARG), more recent develop-
ments in immunohistochemistry (IHC), in situ hybridization histo-
chemistry (ISHH), transcriptome approaches such as DNA
microarrays and ex vivo/in vivo electrophysiological methods have
greatly contributed to our understanding of the regulation of the
PVN/SON activity by GPCR-based signaling. The PVN and SON are
highly vascularized and blood vessel elements and ‘supporting’
cells such as glial cells express GPCRs. In the following sections
we focus on the expression of GPCRs in neurons of the rat PVN
and SON, although it should be emphasized that this has not been
conclusively demonstrated in all studies, e.g., receptor ARG and
DNA microarray experiments.
4.1. Intracellular signaling components in the PVN/SON
We would expect that cells in the PVN and SON are equipped
with the appropriate sets of receptors and various intracellular sig-
naling components to sense and respond to perturbations in
homeostasis. Regulation of both GPCR signaling molecules and
GPCRs themselves (see Section 5) will contribute to the adaptive
responses of the PVN and SON. The distribution of various GPCR
cytoplasmic signaling components in the PVN/SON has not been
extensively studied, although the function of various G proteins
and other intracellular signal transduction mediators involved in
GPCR-mediated effects has been implicated in a number of studies.
Immunoreactive (ir)-Gb1–5 and c3 are expressed at low levels in
the rat PVN and the expression of the various b subunits is
increased by repeated restraint [178,191]. While ISHH studies
suggest that there are very low levels of PKC subunit mRNAs in
the rat PVN and SON [32], other studies point to the expression
of ir-PKC-d in neuronal cell bodies in the PVN/SON, and ir-PKC-/
in PVN ﬁbers [138], and phosphatidylcholine speciﬁc phospholi-
pase C-mediated VP release from the hypothalamus in vitro
appears to involve PKC activation [343]. Osmotic stimulation
increases Gai and Gas mRNAs in the magnocellular PVN and
SON, and cAMP in the SON [368], while Gaq appears to participate
in high-salt induced VP secretion in Dahl salt-sensitive rats [336].
Of the nine adenylate cyclase isoforms only type 2 appears to be
strongly expressed in the PVN and SON [227]. Elevated cAMP with-
in PVN/SON neurons may stimulate cAMP response elements in
gene promoters to alter neuropeptide (or GPCR) gene transcription,
exempliﬁed by studies showing cAMP-driven CRF and VP gene
expression in the PVN [9,42,139,356]. The PVN and SON also
express mRNAs for numerous members of the regulators for G
protein signaling (RGS) family including RGS4, 5, 7, 8 and 9 [101]
– these proteins modulate the function of the Ga and Gb subunits,
and the gene expression of at least one member (RGS4) in the PVN
has been shown to be downregulated by repeated stress [237].
Other studies suggest that the spatial distribution of some signal-
ing molecules within the PVN may be functionally relevant, e.g.,
RGS4 and Gaq/11 mRNAs are found in both pPVN and mPVN
neurons while RGS7 gene expression is conﬁned to the mPVN
[292].
Gene expression proﬁling [124] considerably extends early
studies [194] cataloguing some GPCR-related signaling molecules
in the PVN and SON. A plethora of gene transcripts relevant to
GPCR signal transduction has been revealed (see SupplementaryTables 1 and 2), including those encoding the relatively abundantly
expressed Ca2+-binding calmodulins, endocytosis adaptor mole-
cules dynamin and clathrin, various RGS and G proteins, and a
number of PKC, phospholipase C and D, and cAMP isoforms. While
the presence and anatomical distribution of the majority of these
transcripts has not been validated by other criteria (e.g., IHC, ISHH,
RT-PCR), the data indicates that the PVN and SON express a consid-
erable network of intracellular signaling proteins that could poten-
tially be enlisted upon GPCR activation.
4.2. Detection of GPCR proteins by receptor autoradiography (ARG)
The advent of molecular biological techniques that resolved the
genetic ﬁngerprint of GPCRs led to the popular use of GPCR anti-
bodies – generated from predicted protein sequences of cloned
GPCR DNA sequences – to visualize GPCR protein expression by
techniques such as IHC. Prior to this receptor ARG was a popular
tool to delineate GPCR binding sites in brain and peripheral tissues
since it provided the ability to anatomically resolve receptor
protein expression and to quantitate receptor levels. The method
can give higher (cellular) resolution if tissue sections are apposed
against emulsion-coated coverslips [365] rather than against
X-ray ﬁlm. A major consideration when using receptor ARG is that
not all pharmacologically deﬁned binding sites necessarily
represent physiologically active receptors – in a famous ‘caveat’
to those undertaking receptor studies, Cuatrecasas and Hollenberg
[62] described how iodinated insulin appears to bind with high
afﬁnity to non-biological surfaces like talc with characteristics –
except ‘biological activity’ – that are commonly attributed to
speciﬁc hormone–receptor interactions. Moreover, while radiola-
beled ligands may bind ‘functional’ (capable of binding an agonist)
GPCRs they may not bind to the entire receptor pool e.g., they may
only bind to high afﬁnity binding sites, receptor–G protein interac-
tions critical for agonist binding may be disrupted during the
receptor ARG procedure, and ‘immature’ GPCRs that have not been
post-translationally modiﬁed and/or possess the requisite tertiary
structure, or degraded GPCRs may not bind the ligand. Other
limitations of the technique include the masking of binding sites
by endogenous ligand, although this is usually minimized by buffer
pre-washes prior to ligand incubation. Receptor binding studies on
tissue homogenates (infrequently if ever used for GPCR expression
in the PVN/SON) or receptor ARG are critically dependent on the
speciﬁcity and selectivity of the radiolabeled ligand employed –
high afﬁnity radioligands selective for a particular GPCR subclass
are not always available. Speciﬁc binding is deﬁned as for receptor
binding assays on tissue homogenates, and includes diminution of
bound radioactivity by the addition of excess cold ligand and
establishing a pharmacological proﬁle using closely- and dis-
tantly-related compounds. Knockout mice (providing the distribu-
tion of GPCRs in rat and mouse are the same) are an invaluable
addition in validating radioligands for a speciﬁc receptor. Detection
of low amounts of protein also depends on the sensitivity and
speciﬁc activity of the radioligand, e.g., iodinated versus tritiated
ligands can be used for shorter exposure times against ﬁlm but
offer lower resolution. An example of receptor ARG for the apelin
APJ receptor is shown in Fig. 2. In this particular case there is
almost a perfect overlap between APJ binding sites and APJ mRNA
as shown by ISHH [243] – such a strong correlation between recep-
tor protein and mRNA is not always the case since GPCR mRNA is
present primarily in cell bodies whereas the corresponding protein
may be present at distant sites, e.g., on projecting axon terminals.
IHC and ultrastructural studies are mandatory to address the
potential mismatch between GPCR protein and GPCR mRNA in
the brain.
The list of the 25 GPCR subfamilies detected in the PVN/SON by
receptor ARG is shown in Supplementary Table 3. The number is
Fig. 2. Receptor autoradiographical localization of the apelin APJ receptor with the APJ agonist 125I-(Pyr1)apelin-13 in 20 lm sections of adult male Sprague–Dawley rat brain.
APJ ARG was performed with modiﬁcations of a previously described procedure [156]. Sections were incubated with 0.5 nM 125I-(Pyr1)apelin-13 (Perkin Elmer,
Cambridgeshire, UK) alone (A,B) or in the presence (C) of 1 lM cold ligand ((Pyr1)-apelin-13; Bachem, Germany), and exposed to emulsion-coated X-ray ﬁlm (Amersham
Hyperﬁlm 3H) for 25 days which was then developed manually as per the manufacturer’s instructions. APJ binding sites in brain structures coincides with the mRNA
distribution (see Fig. 4H in [243]) – binding in the SON is obscured by the intense labeling of the basal (free) surface of the hypothalamic diencephalon (arrowheads). Arrows
point to APJ binding in the dorsal surface of the thalamus. B and C are a magniﬁcation of the PVN – labeling (B) present in both the magnocellular and medial parvocellular
PVN is displaced by excess cold ligand (C). Scale bars, 200 lm.
50 G.G.J. Hazell et al. / Frontiers in Neuroendocrinology 33 (2012) 45–66likely incomplete since not all the literature covering GPCR
receptor ARG in the brain encompasses the pertinent hypothalamic
levels, and even when the relevant brain levels have been included
in some studies it is often difﬁcult to ascertain if binding is above
background levels. Critically receptor ARG (and other receptor pro-
tein or RNA detection techniques) does not directly inform about
GPCR function. This can be addressed in part by ‘functional’ ARG
with [35S]GTPcS to map region-speciﬁc, GPCR ligand-dependent
activation of G proteins [112,303]. Although it has not used exten-
sively in the PVN and SON, [35S]GTPcS binding ARG has demon-
strated ‘active’ neuropeptide Y1 and Y2 [286], and cannabinoid
CB1 [121] binding sites in the PVN. Positron emission topography
(PET) is an alternative imaging technique to visualize GPCRs non-
invasively in the PVN and SON in vivo; while the technique is
relatively low resolution and there is a dearth of suitable GPCR
ligands for such studies, there are a few publications (e.g., 5-HT1A
receptors in the rat PVN [12]) indicating that this approach may
be a useful adjunct to receptor ARG studies in the future.
Receptor ARG rarely has the sensitivity or resolution of IHC.
Moreover, in the absence of selective ligands to deﬁne a GPCR fam-
ily in the PVN/SON, IHC and/or ISHH with subtype-selective anti-
bodies and DNA/RNA probes, respectively, can elaborate a
speciﬁc GPCR receptor subtype.
4.3. Immunohistochemistry (IHC) to visualize GPCR expression
Since GPCR-speciﬁc and -selective ligands are not available for
all GPCRs, antibodies have been a popular option to detect many
GPCRs. IHC employing primary GPCR antibodies traced with sec-
ondary antibodies to permit ﬂuorescent or chromogenic detection
of ir-proteins is a valuable technique to localize GPCR expression in
sections of the PVN and SON, offering a far greater lateral and axial
resolution than receptor ARG. A major consideration in all GPCR
protein and mRNA detection techniques is speciﬁcity. The GPCR
ﬁeld is awash with reports of GPCR antibodies that don’t ‘work’ be-
tween laboratories, those that have stopped working after new
batches were purchased, and those that give no staining. For anti-
bodies in particular and the IHC method in general, the evaluation
of speciﬁcity has provoked numerous comments in the past with
many concluding that antibody speciﬁcity is a difﬁcult criterion
to fulﬁl [315]. There are well-established controls for IHC proce-
dures, including the absence of staining when the antibody is
pre-absorbed with the immunizing antigen, although this only
proves that the antibody bound the added antigen and not that
the antibody is ‘speciﬁc’ for the GPCR, and the presence byWestern
blotting of the appropriate GPCR molecular sizes which may corre-
spond to post-translationally modiﬁed and/or oligomeric forms.However, other points related to antibody use and storage (e.g.,
possibility of ‘carrier’ antibodies contributing to staining patterns;
tendency of antibodies to form aggregates at 4 C; potential insta-
bility of immunoglobulin fractions or afﬁnity-puriﬁed antisera;
prolonged storage times between ﬁxation, sectioning and staining;
inefﬁcient blocking of immunoglobulin Fc receptors (which are
present in the PVN/SON [124]) – e.g., see [348] tend to be
under-appreciated and often overlooked, and can lead to increased
non-speciﬁc, or variable or complete absence of speciﬁc staining.
Alterations in IHC staining patterns between different antibody
batches (either from different animals or different bleeds from
the same animal) can often be explained by the inherent character-
istics of the normal immune response, e.g., decreasing antibodies
titers, or high-afﬁnity antibodies present in an early bleed may
be replaced by high-avidity antibodies (perhaps with a lower rela-
tive concentrations of speciﬁc versus ‘less-speciﬁc’ immunoglobu-
lins) as the immune response proceeds. The majority of GPCR
antibodies for IHC are raised to short, synthetic GPCR peptides
(‘haptens’) usually coupled to a carrier (e.g., keyhole limpet hemo-
cyanin or sometimes bovine serum albumin) to enhance the anti-
hapten antibody response, or less frequently to partially puriﬁed
native or recombinant GPCRs. Invariably the antibodies are a poly-
clonal mixture (monoclonal antibodies have only been used occa-
sionally (e.g., see [275,288,370]) and directed to regions that are
most divergent between different GPCR subclasses, N- or C-termi-
nus moieties being the most attractive targets. Most GPCRs are
post-translationally modiﬁed [53,326,350], a crucial point in GPCR
antibody production since regions that can be potentially glycosyl-
ated, phosphorylated or acylated in vivo may mask an epitope to
hinder antibody recognition. On the ﬂip side, phosphospeciﬁc
GPCR antibodies can be made (e.g., [330]). Antibodies can also con-
ceivably differentially react to ligand-activated versus unoccupied
GPCR conformations, and antibodies raised against denatured
GPCR proteins may not recognize the ‘native ‘ (usually ﬁxed) GPCR
in tissue sections.
For GPCRs, serious speciﬁcity concerns have been raised in a
number of articles contesting the reliability of many GPCR antibod-
ies for IHC (e.g., [224]). In contrast the speciﬁcity of antibodies to
neuropeptides and other cellular constituents are rarely indicted
to the same degree, commensurate with the diverse, largely struc-
turally non-conserved nature of GPCR ligands compared with the
often, high amino acid homology between different GPCR
subtypes. A recent review of studies using antibodies against 19
a1- and b1-adrenoceptor, acetylcholine, dopamine and galanin
receptor subtypes for immunoblotting and IHC concluded that
apparent lack of speciﬁcity of GPCR antibodies appears to be the
rule rather than the exception [224]. Some sensible suggestions
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[149,224]. These include the reduction of immunostaining follow-
ing GPCR knockdown using RNA interference (although a lack of
knowledge of GPCR mRNA and protein turnover may make this
problematic – see Section 5 below) and obtaining similar staining
patterns with antibodies against different GPCR epitopes, although
it is rare to ﬁnd studies using two or more antibodies to detect
GPCRs by IHC in the PVN and SON (exceptions include the
dopamine D4 [67] and glutamate mGlu1 [161] GPCRs). Similarly,
the absence of GPCR immunostaining in GPCR knockouts has also
been advocated as a desired IHC control [224]. Assuming that an
antibody is truly GPCR-speciﬁc in both rats and mice, and there
are no species differences in the GPCR distribution between these
animals, the absence of immunostaining in tissues from a knockout
animal in which the entire GPCR protein coding sequence has been
eliminated should serve as an excellent ‘negative’ control in IHC on
rat tissues. However, if the knockout targeting construct does not
include the relevant protein region to which the antibody was
raised, it is possible that the antibody could react to a protein
translated in-frame from the targeting construct in vivo, and lack
of staining is not a foregone conclusion. While we do not necessar-
ily share the outlook that the speciﬁcity of most GPCRs is suspect, a
review of the literature emphasizes that caution is warranted,
especially when using some commercially prepared antibodies
[105,256]. We have not endeavored to evaluate the speciﬁcity of
antibodies used to detect GPCRs in the PVN and SON. However
the expression of many GPCRs detected by IHC (see Supplementary
Table 4) has been validated by other methods (which also have
their own speciﬁcity issues).
Individual GPCR numbers per cell are usually quite low in the
brain, with lower estimates ranging from 100 to 300 receptors
per cell (very low copy number) to upwards of 2000–6000 recep-
tors per cell (around physiological levels for many GPCRs – e.g.,
see [152] and references therein)). By way of comparison, cells
engineered to express recombinant GPCRs can achieve levels of
greater than 100,000 receptors in each cell. The threshold of detec-
tion for a ‘good’ antibody in IHC is probably in the order of 10–1000
receptors per cell depending on the staining and microscopical
method used (e.g., see [54,73]). The detection of ir-GPCRs in cell
bodies, axons, dendrites and terminals, and in intracellular organ-
elles such as endosomes, endoplasmic reticulum and the nucleus
by IHC with conventional light microscopy can be facilitated by
the use of high-resolution optical imaging techniques like confocal
microscopy. GPCRs are highly mobile and trafﬁc between different
subcellular compartments in the PVN and SON, and are probably
dendritically sorted as in other brain regions [269]. For example,
IHC has revealed that the tachykinin NK3 receptor translocates to
the nucleus of VP and non-VP PVN neurons in a stimulus-depen-
dent manner, where it may play a role in transcriptional regulation
[110,131].Fig. 3. Double label immunoﬂuorescence for GPER and VP in the adult. male Sprague–D
merged (C; overlap yellow). 50–70% and 40–60% of VP and OT magnocellular neurons, re
[116]. OC, optic chiasm; SON, supraoptic nucleus. Scale bars, 50 lm.CNS GPCRs are not particularly abundant proteins and their sig-
nals (and non-speciﬁc staining) can be enhanced by using modiﬁed
IHC protocols incorporating tyramide signal ampliﬁcation (TSA)
[25]. Even with improvements in IHC detection, however, it is often
difﬁcult to discern whether GPCR staining is associated with the
cell surface in detergent (e.g., Triton X-100)-treated sections of
ﬁxed tissue, although there are some examples of uniform or punc-
tate staining closely apposed to the plasma membrane (e.g., tach-
ykinin NK3 [131]; PTH2 parathyroid hormone [341] receptors). In
most cases in the PVN and SON ir-GPCR staining is quite nonde-
script and apparently found mainly intracellularly, which has
important functional implications for some GPCRs that are thought
to be active inside the cell (e.g., the putative estrogen receptor
GPER [266]). For the majority of GPCRs, an intracellular versus
plasma membrane distinction may ‘simply’ reﬂect the detection
of mature GPCRs in the endocytic pathway and/or immature GPCR
pools (presumably functionally inactive) yet to be presented to the
plasma membrane. In a few instances light microscopic studies
have been reinforced by higher magniﬁcation immuno-electron
microcopy, e.g., in the PVN and SON ir-GABAB1 is mainly associated
with the endoplasmic reticulum, golgi apparatus and large mem-
brane-bound vesicles, while a small amount of staining is found
close to the plasma membrane [268]. The possible functional rele-
vance of ir-GPCR localization in PVN and SON neurons is supported
by other studies, e.g., staining for the CB1 cannabinoid receptor, a
GPCR that inhibits the release of excitatory and inhibitory neuro-
transmitters in the brain [253], is clearly present in GABAergic ter-
minals and ﬁbers surrounding oxytocinergic PVN neurons [45]. The
CB1 receptor appears to be synthesized in the PVN and SON [217]
but other GPCRs such as the prostanoid EP3 receptor [234] appear
to be conﬁned to ﬁber terminals presumably as part of afferent
projections to the PVN/SON. So IHC can give some idea of the
pre/post-synaptical localization of GPCRs in the PVN and SON.
Strong indirect evidence that GPCRs in the PVN and SONmay be
functionally important also comes from studies where ir-GPCRs
have been localized to phenotypically-identiﬁed neurons. For
example, a1D-adrenoceptor [280] and angiotensin AT1A [245]
receptors are both located in pPVN CRF-expressing neurons, the
5-HT1A/2A [370], apelin APJ [327], chemokine CXCR4 [44], estrogen
GPER [31,116] – see Fig. 3.), GABAB1/B2 [268], j opioid [299] and
tachykinin NK3 [110] receptors are expressed in VP and/or OT
neurons, whereas the glutamate mGlu1 receptor has been identi-
ﬁed in both CRF and VP neurons [165]. VP, OT and CRF (and TRH,
dopamine, GHRH and somatostatin) neurons in the PVN and SON
also express additional neuropeptides that could be co-regulated
[39]. The presence of VP V1A receptors on VP neurons [133] and
OT receptors on OT neurons [215] suggests that these receptors
may act in an autocrine fashion to regulate the release of their
own cognate ligands. Moreover, the demonstration that some
GPCRs (e.g., apelin APJ [327], estrogen GPER [116], and parathyroidawley rat SON. Images for GPER (A; red) and VP (B; green) immunoreactivity were
spectively, express ir-GPER [116]. Antibodies and method are described previously
52 G.G.J. Hazell et al. / Frontiers in Neuroendocrinology 33 (2012) 45–66hormone PTH2 [341] receptors) are present on both PVN and SON
neuronal cell bodies, ﬁbers and terminals (e.g., in the median
eminence or in the posterior pituitary) suggests that GPCRs may
act at different locations to alter neuropeptide or neurotransmitter
synthesis and/or release (see Fig. 1). Based on its intracellular, and
to a minor degree cell surface localization, the estrogen GPER
receptor is an example of a GPCR that may be functionally active
on or in neuronal cell bodies in the PVN and SON, dendrites, and
axonal projections through the internal zone of the median
eminence and posterior pituitary nerve terminals [116]. Given
the breadth of ir-GPCR distributions in the PVN and SON, and the
estimated number of neurons in the PVN and SON (e.g., there are
about 1000 and 3000 VP neurons in the rat PVN and SON, respec-
tively, and approximately 1250 OT neurons in both nuclei – [267],
it is extremely likely thatmanyGPCRsare co-expressed in individual
neurons. In fact, the possible co-existence of two (ormore) different
GPCRs in the same neuron would support the concept that GPCRs
may physically interact (see Section 6 below) in the PVN and SON.
However, demonstrating co-expression of two or more proteins in
a cell is difﬁcult, although not impossible (see [33,235]) using anti-
bodies raised in the same species to detect non-abundant proteins.
In the SON and elsewhere in the brain GPCR co-expression appears
to be the case for the two subunits (each a 7TM ‘receptor’) of the
GABAB receptor, GABAB1 and GABAB2 [268], which must heterodi-
merize for functional GABAB responses [216].
There are a number of mismatches between GPCR protein and
mRNA as determined by receptor ARG and/or IHC and ISHH,
respectively. For example, binding studies with an iodinated
glucagonGLP-1 receptor agonist detect dense labeling in themedian
eminence and posterior pituitary where there is no GLP-1 receptor
mRNA [100,293]. Conversely, GLP-1 receptormRNA is concentrated
in the PVNwhere onlyweak binding is observed andwhere ir-GLP-1
ﬁber terminals are closely associated with OT- and CRF-expressing
neurons [324]. The apparent discrepancies between GPCR protein
and mRNA localizations highlight technical issues (e.g., sensitivity)
and where GPCR transcription in cell bodies, translation in cell
bodies and perhaps axons and dendrites, and transport along axonal
and dendritic ﬁbers may occur in the PVN and SON.
4.4. In situ hybridization histochemistry (ISHH) localization of GPCR
mRNA
ISHH was introduced in 1969 [40,91,147] as a method to detect
speciﬁc mRNAs within cells by hybridizing labeled RNA, cDNA, or
short oligonucleotide DNA probes to target sequences in tissue
samples. Employing IHC in concert with ISHH can provide converg-
ing anatomical evidence to form testable hypotheses and support
data on GPCR function in the PVN and SON. High throughput ISHH
as advocated for mapping high-resolution gene expression in the
brain ([182] – see Allen Brain Atlas @ http://brain-map.org) is usu-
ally satisfactory for abundant genes. Apart from a few notable
exceptions such as the cannabinoid CB1 receptor gene that is
highly expressed in many brain regions [217], most GPCR mRNA(s)
are not as abundant as those encoding ionotropic receptors and are
visualized usually after weeks–months exposure against X-ray ﬁlm
or photographic emulsion. However, reﬁnements in the ISHH
method permit the detection of as few as 10–20 mRNA copies
per cell [294], sensitive enough to visualize the majority of the rar-
est GPCR transcripts, and to compare changes in GPCR gene expres-
sion at the cellular level by counting silver grains or at the
macroscopic level by image analysis and densitometry with refer-
ence to the appropriate autoradiographic standards (as for receptor
ARG). ISHH detection sensitivity can also be enhanced by using
multiple oligonucleotide probes to different regions of the desig-
nated mRNA, or by a number of ampliﬁcation methods such as
TSA (see Section 4.3 above).Cloning of the mammalian GPCR cDNAs, or identiﬁcation of
GPCR DNA sequences using homology-based searching tools, has
provided the platform to map GPCR transcript expression in the
brain by ISHH. More often than not 35S-labeled antisense RNA
probes targeting a large part of the GPCR mRNA (e.g., approx.
300–600 bp RNA probes (riboprobes) for proteins whose coding
regions average about 1000–1500 bp in length) are used for opti-
mal GPCR transcript detection: these can be labeled to a higher
speciﬁc activity, and bind more strongly to target mRNA se-
quences, than oligonucleotide probes. The use of long riboprobes
and even short oligonucelotides (typically 40–48 bp) introduces
its own set of problems since hybridization to closely related GPCR
subtypes may occur if probes are designed to a relatively well-con-
served part of the GPCR mRNA sequence. GPCR-subtype speciﬁcity
is usually increased if regions such as the 30-untranslated (UTR) of
GPCRs are targeted (providing the G/C content of the probe is not
so low to preclude high stringency washes). However, speciﬁcity
concerns may also be compounded if sense probes used as negative
controls for antisense probe binding label the tissue of interest
(one deﬁnition of ‘non-speciﬁc’ hybridization), which is not
implausible since over 50% of the mammalian genome can produce
transcripts from both DNA strands [155]. Evidence that the com-
plementary DNA strand of a GPCR gene can code for another gene
is provided by the study of Foletta and coworkers [85], where a
sense VP V2 receptor probe which does not hybridize to the V2
receptor-expressing kidney [247], detected transcripts for a Rho
GTPase activating protein in the brain. It is generally advised to
use well-characterized probes (e.g., ones that has been validated
by Northern blots, and gives appropriate hybridization patterns
in control tissues), or more than one probe (and corresponding
sense ‘control’) against a target sequence to minimize erroneous
interpretations of ISHH labeling patterns. Our experience and that
of many other laboratories using ISHH is that, as in the case of anti-
bodies and IHC, there is often signiﬁcant variability in the signal/
noise ratios for different probes directed to the same GPCR mRNA
target.
As outlined in Supplementary Table 4, a large number of GPCR
mRNAs have been detected in the cell bodies of PVN and SON neu-
rons. By and large there is general agreement on steady-state GPCR
gene expression in the PVN and SON between laboratories but
some exceptions are apparent in the literature. For example, while
Hurbin and coworkers [132,133] detected VP V1B receptor mRNA
and protein expression in the mPVN and SON using short oligonu-
cleotide probes and receptor antibodies, respectively, others found
only occasional V1B receptor mRNA-expressing cells in the pPVN
using riboprobes directed against the 30UTR of the receptor [366].
Studies such as these emphasize the importance of probe speciﬁc-
ity and the limits of ISHH, and raise questions of mRNA and protein
turnover (see Section 6).
Like IHC, ISHH is also amenable to co-expression studies,
whether combined with IHC or alternatively used alone to investi-
gate the expression of two distinct transcripts in neuronal cell
bodies. For example, 5-HT2C [118], adrenoceptor a1B [65], CRF1
[136] and melanocortin MC4 [201] receptor mRNAs are predomi-
nantly found in CRF neurons, neuromedin U NMU2 receptor mRNA
is mainly present in OT neurons [260], and neuropeptide Y Y1
receptor transcripts are co-expressed with TRH mRNA in pPVN
cells [160]. Of the 52 GPCRs with known ligands detected in the
PVN by IHC, 34 of the corresponding mRNAs have also been
detected in the same or independent studies (see Supplementary
Table 4). A further 9 orphan GPCR mRNAs are also present in the
PVN/SON as detected by ISHH (see Supplementary Table 7).
Examples of the ISHH patterns of some of these are shown in
Fig. 4. The great majority of GPCRs are expressed in both the
pPVN and mPVN (e.g., 5-HT1A/2A [370]; a1D-adrenoceptor [280];
apelin APJ [243,327]; calcium-sensing CaS [272]; CRF1 [136];
Fig. 4. Examples of in situ hybridization histochemistry (ISHH) for some orphan GPCR mRNAs, and the putative estrogen receptor GPER mRNA (columns), in sections of SON/
PVN/hippocampus and pituitary gland (rows) from adult male Sprague Dawley rats. Images are of 12 lm sections hybridized with 35S-UTP labeled riboprobes exposed to ﬁlm
(Amersham Hyperﬁlm MP) for 6 weeks. As the distribution of the rat GPER mRNA (and protein) has been well characterized [116], and is expressed at low levels in the PVN
and SON, the GPER probe acted as a positive (method) control for the orphan probes. A comprehensive mRNA (or protein) distribution for most of the orphans has yet to be
described. The GPER probe clearly labels the SON (thin arrow), PVN (ﬁlled thick arrow), and anterior and intermediate lobe (long dashed arrow) of the pituitary gland, while
no signal is present in the neural lobe. An extremely faint signal is also observed in the SCN (unﬁlled thick arrow) and CA1/CA2 and CA3 hippocampal regions. The positional
arrows of labeled structures shown in the GPER distribution are indicate in subsequent images for the orphan GPCRs. GPR56 transcripts appear to be ubiquitously distributed
throughout the sections shown, although a more intense labeling is seen in the SON, CA1–3 and the lateral ventricles (short dashed arrow), and to a lesser extent in the PVN.
The intermediate lobe and neural lobe of the pituitary are also intensely labeled with the GPR56 probe, while the anterior pituitary is moderately labeled. GPR108 mRNA is
highly expressed in the SCN, SON, PVN, CA1–3 (and dentate gyrus), dorsal third and lateral ventricles, and all three lobes of the pituitary (anterior and intermediate
lobe > neural lobe). GPR125 mRNA expression is observed in the dentate gyrus and CA3 of the hippocampus, and the dorsal third and lateral ventricles, with faint expression
seen in the PVN/SON. The anterior lobe of the pituitary are strongly labeled with the GPR125 probe with faint, diffuse signal in the intermediate and neural lobes. GPR146
mRNA is present in the PVN/SON, and is highly expressed in the dorsal third and lateral ventricles and anterior lobe of the pituitary, with moderate/faint expression found in
intermediate and neural lobes. GPR153 labeling is striking throughout the thalamus, in the SCN, and in several cortical layers, with moderate signal in the PVN/SON, and weak
expression in CA1–3 of the hippocampus and anterior pituitary. Sections hybridized with sense riboprobes for all GPCRs as controls showed only background/or were absent
of hybridisation signal (data not shown). 3 V, third ventricle; SCN, suprachiasmatic nucleus; PVN, paraventricular nucleus; Th, thalamus; CA1–CA3, CA1–CA3 regions of the
hippocampus; D3 V, dorsal third ventricle; LV, lateral ventricle; AP, anterior pituitary; IL, intermediate lobe of the pituitary; NL, neural lobe of the pituitary. The rat orphan
GPCR probes were generated by PCR using 125 ng rat genomic DNA (extracted from rat testis) as a template. PCR primers incorporating recognition sequences for restriction
endonucleases (underlined) were used to generate products of approximately 300–500 bp in size. All probes were targeted to the 30-untranslated (UTR) region (or C-terminal
into 30-UTR in the case of GPR125) of each GPCR mRNA. GPR56 primers, upstream: 50-CCTCTGAATTCGGGGTGCACATGCATGGC-30; downstream: 50-CAGA-
CAAGCTTGGAAGATGCTCAGCTCCTA-30 , corresponding to bp2376–2844 of the rat GPR56 gene (Genbank Accession number NM_152242) were used to generate a 469 bp
product which yielded a 453 bp probe when digested with EcoRI–HindIII. GPR108 primers, upstream: 50-ACTTCCCCGAGTTCAGAGATCCGCCTTC-30; downstream: 50-
AATCAAAGCTTTATGAAGCCCAGGCTCT-30 , corresponding to bp1749–2093 of the rat GPR108 gene (NM_199399) were used to generate a 345 bp product which gave a 329 bp
probe following digestion with AvaI–HindIII. GPR125 primers, upstream: 50-CCAAGGAATTCAGCTGCAGCTGA CCTTGA-30; downstream: 50-TTTTTAAGCTTTGGGGAAGGGCA-
ATTTAG -30 , corresponding to bp4198–4549 of the rat GPR125 gene (XM_223485) were used to generate a 352 bp product which gave a 336 bp probe when digested with
EcoRI–HindIII. GPR146, upstream: 50-GGGCCGAATTCCAAGGAGAGGGCCTGACCA-30; downstream: 50-TCCTCAAGCTTTAACACTGGTATTTGCGA-30 , corresponding to bp1202–
1718 of the rat GPR146 gene (XM_573364) were used to generate a 517 bp product which yielded a 501 bp probe following digestion with EcoRI–HindIII. GPR153, upstream:
50-CCCCAGAATTCATGCAGACGGAAGAGGC-30; downstream: 50-AAGGAAAGCTTGCTCAATAGAACTTGTT-30 , corresponding to 2059–2521 of the rat GPR153 gene
(NM_001034855) were used to generate a 463 bp product which gave a 447 bp probe after digestion with EcoRI–HindIII. Recognition sequences for endonucleases
facilitated cloning into the RNA-generating vector pGEM4z (Promega, WI, USA), and sense and antisense probes were generated using T7 and SP6 polymerases (antisense:
generated with T7 polymerase following linearization with the opposing restriction endonuclease; sense: generated with SP6 polymerase following linearization with the
opposing restriction endonuclease) with 35S-UTP and the MAXIscript in vitro kit (Ambion, TX, USA). The integrity of each probe was veriﬁed by DNA sequencing. Rat GPR30
probes were generated as previously described [116]. All in situ hybridization experiments were performed as described in detail at http://intramural.nimh.nih.gov/lcmr/
snge/Protocols/ISHH/ISHH.html.
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GPCRs appear to be preferentially expressed in the pPVN (e.g., con-
sistent with regulating stress or autonomic responses), or mPVN
(e.g., compatible with regulating water homeostasis or reproduc-
tive status) by either IHC and/or ISHH (pPVN: 5-HT2C [118]; angio-
tensin AT1A [245]; prolactin-releasing peptide PRRP [195]
receptors; mPVN: chemokine CXCR4 [44]; neuromedin U NMU2
[260]; j opioid [299] receptors). One GPCR (neuropeptide FF/neu-
ropeptide AF NPFF1) seems to be PVN-speciﬁc in rats [103],
although ir-NPFF1 ﬁbers found just dorsal to the SON, as in humans
[102], may project to the SON [143] and be responsible for the
inhibitory effects of centrally administered NPFF on hypovol-
emia-induced VP secretion into the blood [10].4.5. Transcriptomic analysis of GPCR expression in the PVN/SON
RT-PCR-based methods have been used to delineate a partial
GPCR transcriptome in a number of tissues including mouse heart
[228] and brain [334]. Only the odd study has used PCR to detect
the expression of an individual GPCR gene in dissected PVN/SON
[58,200,291,310]. Large-scale transcriptome analysis of enriched
genes, including some GPCR transcripts, has been performed in a
number of mouse brain regions including striatum, frontal cortex,
hippocampus and amygdala [19,97,183]. Recently DNA micro-
array-based transcriptomal analysis of the rat PVN, SON, subforni-
cal organ and area postrema, and mouse SON was reported from
our laboratories [124,123,122,308]. There are some limitations
Table 1
Summary of GPCRs expressed in the rat PVN and SON.
GPCRs expressed in the PVN and SON
Total number of known
GPCRsa
224
Number of orphan GPCRsa 96 (class A), 29 (class B) and 7 (class C) = 132
Known GPCRs in rat PVN 94 + 7 based on functional criteria + 14
unvalidated arrays
Orphan GPCRs in rat PVN 9 by ISHH + 17 unvalidated arrays
Known GPCRs in rat SON 74 + 6 based on functional criteria + 16
unvalidated arrays
Orphan GPCRs in rat SON 9 by ISHH + 21 unvalidated arrays
a Numbers based on lists in the on-line IUPHAR Database of Receptors and Ion
Channels (http://www.iuphar-db.org/index.jsp) [111] excluding chemosensory
(e.g., olfactory, vomeronasal, taste) receptors and possible spliced (see Supple-
mentary Tables 5 and 6) GPCR variants.
Table 2
GPCR families expressed in the PVN.
GPCR families expressed in the PVN
5-HT Melanocortin
Acetylcholine muscarinic Metabotropic glutamate
Adenosine Neuromedin U
Adrenoceptor Neuropeptide FF
Angiotensin Neuropeptide S
Apelin Neuropeptide W
Bombesin Neuropeptide Y
Bradykinin Neurotensin
Calcitonin Opioid
Calcium-sensing Orexin
Cannabinoid P2Y
Chemokine Parathyroid hormone
Cholecystokinin Peptide P518 (QRFP)
Corticotropin-releasing factor Prokineticin
Dopamine Prolactin-releasing peptide
Endothelin Prostanoid
Estrogen Relaxin
GABAB Somatostatin
Galanin Tachykinin
Ghrelin Thyrotropin-releasing hormone
Glucagon Urotensin
Histamine VIP & PACAP
Melanin-concentrating hormone Vasopressin and oxytocin
There are 46 GPCR families expressed in the PVN, including 33 different peptide
classes (in italics). Notably absent are lipid-like GPCRs (e.g., lysophospholipids)
which were detected in DNA microarrays but whose presence in the PVN (or SON)
has not been validated, and the anaphylatoxin, formyl peptide, kisspeptin, leuko-
triene, melatonin, motilin, platelet-activating factor, and trace amine GPCRs for
which there are functional responses in the PVN following central or peripheral
administration of agonists, or in HNS cultures in vitro. The vast majority of GPCRs
expressed in the PVN are also present in the SON – the exceptions are members of
anaphylatoxin, formyl peptide, leukotriene, platelet-activating factor, and trace
amine GPCRs which have not been demonstrated in the SON to our knowledge. To
date members of the bile acid, free fatty acid, glycoprotein hormone, gonadotropin-
releasing hormone and hydroxyl acid GPCRs families do not appear to be expressed
in either the PVN and SON.
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ously [124]. For example, manual rather than laser dissection of
PVN and SON was used so a small amount of surrounding tissue
such as the 3rd ventricle could have been included in the samples.
In addition, most but not all GPCRs with known ligands, or orphan
GPCRs are represented on the Affymetrix 230 2.0 rat genome chip
interrogated – examples of some ‘missing’ GPCRs include the bom-
besin BB3 receptor and the orphan GPCRs GPR101 and GPR165.
Furthermore, some rare GPCR transcripts in the PVN and SON may
escape detection, or some probe sets may have failed in some or
all of the replicates, thus excluding them from analysis – examples
of this are the apelin APJ, estrogenGPER, and VPV1A receptorswhich
are readily detected by receptor ARG, IHC and/or ISHH in the PVN
and SON. Bearing these points in mind, we have constructed a list
of the GPCRs genes considered present by DNA microarrays in the
PVN and SON (Supplementary Tables 4–6). The relative abundance
of GPCR transcripts in both hypothalamic nuclei varies from those
that are highly expressed such as various GABAB subunits, and
neurotensin NTS2 and endothelin ETB receptors, to the less highly
expressed purinergic P2Y13, adenosine A3, and metabotropic gluta-
mate mGlu4 and mGlu7 receptors. About 80% of GPCR transcripts
in the PVN are also present in the SON, and approximately 70% and
50% of transcripts for GPCRs with known ligands in the PVN and
SON, respectively, has been validated by receptor ARG, IHC and/or
ISHH. This includes some GPCR transcripts (e.g., parathyroid
hormone PTH1 and neuropeptide Y Y5 in the PVN/SON) that are
towards the lower limits of detection. The GPCR gene lists include
14–16 ‘new’ GPCRs with known ligands, such as adenosine A2B,
chemokine CXCR3 and CXCR7, lysophospholipid LPA1 and S1P1,
metabotropic glutamate mGlu4, purinergic P2Y13 and protease-
activated PAR1 receptors, and 17–21 ‘new’ orphan GPCRs (see Sup-
plementary Table 7) whose localization in the PVN and SON is
unvalidated on review of the literature, and which may represent
novel targets for future physiological studies. Another interesting
feature of the transcriptomic data is that by virtue of multiple
oligonucleotide probe sets representing some genes on the array
chip, a number of GPCR splice variants appear to be present in the
PVN and SON. Alternate splicing of pre-mRNAs is one mechanism
for increasing diversity in the transcriptome. Although approxi-
mately half of GPCR genes are devoid of introns within their coding
sequence, those that possess introns can theoreticallyundergo alter-
native splicing and this may have consequences on GPCR functions
such as altered pharmacological proﬁles, constitutive activity and
subcellular localization [214]. Examples of GPCRs that exhibit vary-
ing degrees of alternate splicing include the GABAB1 subunit [345],
NOP opioid [361], metabotropic glutamate [240] endothelin ETA
[113] and parathyroid hormone PTH1 [150] receptors, all of which
have potential isoforms identiﬁed by DNA microarrays in the PVN
and SON. Transcriptome analysis of the PVN and SON also reveals
four GABAB1 subunit isoforms (a, f, g, j) – and IHC and ISHH studies
indicate that at least two GABAB1 subunits (B1a and B1b) are
expressed in the PVN and SON [89,22]. There are 12GABAB1 variants
(a-k including c-a and c-b) in total, the majority of which are
secreted forms that may confer functional differences to the
GABAB1/B2 heterodimer [325].
It is very likely that the number of GPCR genes expressed in the
PVN and SON in the DNA microarray studies outlined above is an
underestimate, and would be expanded further by transcriptomic
experiments on single neurons. High throughput, deep/next gener-
ation sequencing (e.g., RNASeq [339]) of single cell cDNA libraries
from pPVN, mPVN and SON neurons, similar to that reported for
electrophysiologically identiﬁed warm sensitive neurons from the
anterior hypothalamic pre-optic area [73], would reveal GPCR
splicing complexity, rare GPCR transcripts and also those GPCR
genes that are co-expressed (and thus are candidates for heterodi-
merization) in PVN/SON neurons.4.6. Numbers of GPCRs in the PVN and SON: an overview
Embracing the data from the various detection methods out-
lined above we have arrived at a conservative estimate of the
number of GPCRs expressed in the PVN and SON (Table 1). Of the
224 known non-chemosensory GPCRs in the rat genome 101 are
present in the PVN (with a further 14 from unvalidated DNAmicro-
arrays), and 80 are present in the SON (excluding another 16 from
unvalidated DNA microarrays). Interestingly, of the 132 orphan
non-chemosensory GPCRs in the rat genome 22 (9 validated) and
24 (9 validated) are present in the PVN and SON, respectively.
The GPCRs encompass the vast majority (33 that are activated by
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families excluding chemosensory and orphan GPCRs present in
the rat genome (Table 2). The estimate includes a few instances
where GPCR ligands appear to have functional effects (e.g.,
anaphylatoxin, formyl peptide, kisspeptin, leukotriene, melatonin,
motilin, platelet-activating factor and trace amine receptors; see
Supplementary Table 9) in the PVN/SON but their presence has
not been conﬁrmed by any of the detection criteria reviewed. It
should also be emphasized that, as far as we are aware, none of
the GPCR cDNAs/genes in the PVN and SON have been sequenced.
Variations in GPCR sequences and/or potential splicing patterns
may have an impact on the function of PVN/SON GPCRs.5. Regulation of GPCR expression in the PVN and SON
There is ample evidence that GPCR expression can be regulated
by, and contribute to changes in PVN and SON neuronal plasticity.
Levels of GPCRs are determined in part by the rate of receptor
protein synthesis, which can be regulated by either transcriptional
or post-transcriptional mechanisms. Unless a reserve of ‘‘spare’’
receptors exists, alterations in cell surface or cytoplasmic GPCR
levels can signiﬁcantly inﬂuence receptor signaling capacity. GPCR
signaling components (e.g., G proteins) themselves are also
dynamically regulated [166,232], and ultimately GPCR expression
and function is dependent on a host of factors that inﬂuence GPCR
desensitization (e.g., following chronic activation of many GPCRs),
redistribution and degradation. The role of many intracellular sig-
naling molecules (such as GRKs and arrestins) is critical in regulat-
ing these processes. RNA regulation is also very complex, with
small RNA molecules like microRNAs (miRs) and piwi-interacting
RNAs linked to transcriptional silencing, and long non-coding RNAs
involved in transcriptional, post-transcriptional (e.g., RNA alter-
nate splicing, translation) and epigenetic regulation [192].
The apparent absence, or low levels of GPCR expression does
not preclude the possibility that some GPCRs may be induced by
perturbations of PVN and/or SON neuronal function (e.g., change
in osmolality, lactation, stress) as in the case of the CRF1 receptor
[206]. Changes in mRNA levels are usually easier to detect by ISHH
compared to changes in protein as measured by IHC, but this obvi-
ously depends on when the mRNA is assayed after experimental
manipulations, since GPCR mRNA turnover may vary considerably.
GPCR mRNA and protein turnover has been primarily established
in cell lines expressing native or cloned GPCRs and could be quite
different in the PVN/SON microenvironment. Half-lives are
highly variable and often cell context-dependent, ranging from
around 2–20 h for both GPCR mRNA (e.g., acetylcholine m1 [177],
a1-adrenoceptor [141], a1-adrenoceptor [278], b2-adrenoceptor
[109], leukotriene BLT1 [305] receptors) and GPCR protein at the
cell surface (adenosine A1/2A/2B/3 [164], a2A/2B/2C-adrenoceptor
[282,353], b2-adrenoceptor [71], calcium-sensing CaS [46], cannab-
inoid CB1 [220] receptors). The mRNA turnover for a number of
GPCRs is also decreased by agonist stimulation [57,109,141,177],
emphasizing the importance of local agonist levels in the PVN
and SON in regulating both GPCR mRNA and protein levels. In a
few of these studies, in contrast to research on GPCR mRNA expres-
sion in the PVN and SON, nuclear run-on experiments (requiring a
million cell nuclei or more) were used to conﬁrm that changes in
mRNA levels were the result of changes in GPCR gene transcription.
Nuclear run on experiments provide a measure of the frequency of
transcription initiation and are largely independent of the effects of
RNA stability. Interestingly, other studies using hybridization of
DNA microarrays with steady-state mRNA versus newly tran-
scribed (nuclear run on) RNA have shown that approximately half
of stress-regulated genes in H1299 lung carcinoma cells are due to
changes in gene transcription with a similar fraction due tochanges in mRNA turnover [77]. A point that may be relevant to
possible GPCR co-expression and cross-talk in the PVN and SON
is that the angiotensin AT1 receptor induces bradykinin B2 receptor
transcription activation via the phosphorylation of cAMP response
element binding protein (CREB) and assembly of p-CREB on the B2
receptor promoter in kidney collecting duct cells [287].
An alternative method to look at gene transcription rates, and
one that is particularly amenable to tissue sections of PVN and
SON, is to examine heteronuclear (hn)RNA levels. The binding of
probes speciﬁc for introns in RNA-coding region of genes can be
used to quantify hnRNA levels as an indirect measurement of the
transcription rate of genes in response to a particular stimulus.
For GPCR genes that contain multiple introns care must be
exercised in choosing which introns to target because they can
be excised from the nascent pre-mRNA at different rates [174].
ISSH with intron-speciﬁc probes has been successfully used to
measure hnRNA changes for relatively abundant neuropeptide
(e.g., VP, OT and to a lesser extent CRF [120,169,369]) mRNAs,
but has not proved particularly useful to assess GPCR transcrip-
tional activity. One exception is the dopamine D2 mRNA distribu-
tion in the brain where hnRNA levels are (as expected) a fraction
of steady-state mRNA levels [87].
There are numerous studies showing that the expression of
PVN/SON neuropeptides, in particular VP, OT and CRF, are develop-
mentally regulated [6,16,317], and that their expression can be
altered by experimental manipulations [42,2]. In comparison,
reports of ontogenetic variations in GPCR expression in the PVN/
SON are scarce, with the transcript or protein level, and/or function
of a few GPCRs including the angiotensin II AT1a (mRNA present in
PVN E19 onwards [241]), neuropeptide Y1 (mRNA present in PVN
P2 onwards coincident with a signiﬁcant increase in NPY-contain-
ing ﬁbers innervating the nucleus [106]), and melanocortin MC4
(mRNA present in PVN and SON at E18 and P27, respectively,
approximating the appearance of melanocortin binding sites
[162,193]) changing developmentally. At least one GPCR in the
PVN and SON is also diurnally regulated – a2-adrenoceptor expres-
sion in the PVN peaks at the onset of dark (when CORT levels are
highest) whereas in the SON the reverse diurnal pattern is
observed [144].
There have been many studies using receptor ARG, IHC or ISHH
to demonstrate alterations in GPCR expression by pharmacological
or physiological manipulations. More recently, transcriptome
approaches have established that dehydration alters the levels of
transcripts encoding the cannabinoid CB1, GABAB1j, melanocortin
MC4, protease-activated PAR1 and somatostatin sst3 receptors in
the rat SON [124]. Changes in GPCR protein and mRNA levels in
the PVN/SON in response to agonist or antagonist administration,
or physiological perturbations such as adrenalectomy, salt-loading,
dehydration, lactation, gestation and stress are commonly less
than twofold, but 8–10-fold or higher increases in GPCR mRNA
have been reported in some instances – e.g., for the apelin APJ
receptor [242] (see Supplementary Table 8). Invariably gene or
protein expression has been imaged over the entire PVN and/or
SON, so any change in cell-to-cell GPCR expression is often
obscured. Importantly, since the vast majority of studies investi-
gate a single experimental time point, it is surprising to note
how often it is assumed that changes in GPCR mRNA reﬂect
changes in GPCR protein levels and perhaps receptor function. That
this may not always be the case is emphasized in studies where the
correlation between mRNA and protein levels has been investi-
gated using transcriptomic- in conjunction with proteomic-
approaches. For example, in kidney inner medullary duct cells a
large number (approx. 1/3) of proteins that showed signiﬁcant
changes in abundance in kidney inner medullary collecting duct
cells following challenge with dDAVP (desmopressin; a VP V2
receptor agonist) did not show a changes in the corresponding
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While this result relies heavily on the quantitative accuracy of the
methods used, it conceivably highlights an important role in post-
transcriptional regulation of protein abundance, and also obviously
reﬂects the dynamics of mRNA versus protein turnover. Impres-
sively, given that the half-life of GPCR mRNA or protein is usually
not known, a number of studies have combined receptor ARG (or
in some cases IHC) with ISHH to show that alterations in GPCR
mRNA levels in the PVN/SON are associated with changes in the
corresponding GPCR protein. A few examples of this are the in-
creases in angiotensin AT1A receptor after antagonist administra-
tion [210,346], and cholecystokinin CCK1 and CCK2 [125,222],
and galanin GAL1 [41] receptors following osmotic perturbations.
There are other, largely unexplored and speculative ways in
which GPCRs in the PVN and SON could possibly be regulated.
One such mechanism is microRNA (miR)-mediated post-transcrip-
tional regulation. There is substantial evidence that the 30-UTR of
proteins can affect mRNA stability and is involved in regulating
gene expression at the post-transcriptional level, and in the case
of some GPCRs such as the opioid receptors the length of the
30-UTR inﬂuences receptor protein level [358]. MiRs are short,
single-stranded non-protein coding RNAs that tend to suppress
target gene expression by binding to their complementary mRNA
sequences usually in introns or exons of the 30-UTR, and have
emerged as crucial modulators of gene expression especially in
synaptic plasticity. The feasibility of mIR-mediated GPCR mRNA
regulation has been demonstrated by miR-23b inhibition of opioid
l receptor expression [358]. Conversely, opioid l receptor agonists
regulate miR-190 activity [372]. Scanning individual GPCRs for
consensus miR binding sites that are conserved between species
would be a starting point for studies on the potential role of miRs
in regulating PVN/SON GPCRs. It is also becoming increasingly
clear that epigenetic control of gene (especially CRF and VP)
expression in the PVN is important in the HPA axis response to
stress (e.g., see [74,233]). DNA methylation and histone modiﬁca-
tions have been shown to coincide with the differential expression
of the opioid l receptors in the brain [135].
As noted previously, some GPCRs have very low expression
levels (e.g., <1000 receptor copies/cell) and ultimately the
demonstration of a ligand-speciﬁc function is paramount. For those
GPCRs investigated, a functional response has generally been
observed where GPCR binding sites, ir-protein and/or mRNA have
been detected in the PVN/SON.6. Functions of GPCRs in the PVN and SON
The actions of numerous neurotransmitters, neuropeptides and
hormones in the PVN and SON have been well documented (e.g.,
[17,63,114,202,204,265,298,316]) and only some salient features
will be described here. The tonic and stimulated activity of the
PVN and SON is regulated by a number of excitatory and inhibitory
neurotransmitters and neuromodulators, including glutamate and
GABA, the main excitatory and inhibitory neurotransmitters,
respectively, as well as a host of other effectors including angioten-
sin II, catecholamines, histamine and numerous other neuropep-
tides that activate GPCRs, and mediators such as humoral factors
and nitric oxide (e.g., [37,38,76,140,151,190,298,331]). This
regulation can occur directly in the PVN or SON via the effects of
neurotransmitters/neuropeptides synthesized within the two
nuclei and/or indirectly by interactions with glutamatergic or
GABAergic interneurons or afferent projections from other hypo-
thalamic or extrahypothalamic areas that innervate the PVN or
SON [82,146,298]. Apparent mismatches between neurotransmit-
ters/neuropeptides and their receptors that are prevalent in the
brain [119] may not be such an issue in the PVN and SON whereGPCR ligands are available from a number of sources within the
nuclei or extra-PVN/SON locations.
In addition to their peptidergic or neurotransmitter phenotypes,
neurons in the pPVN, and mPVN and SON have deﬁned electro-
physiological characteristics. Classically, under basal conditions
OT magnocellular cells are continuously active, whereas the
activity of VP magnocellular cells ranges from continuously active
to robust phasic to relatively silent [36,204]. Early studies
indicated that mPVN and SON neurons have similar electrophysio-
logical properties [11,221,323] whereas pPVN cells exhibited elec-
trophysiological heterogeneity [323]. Neurosecretory neurons
concentrated in the medial pPVN have no low threshold spike
(LTS) and small T-type Ca2+ currents while in non-neurosecretory
cells in the dorsal and ventral pPVN the converse is true [207]. In
magnocellular cells bursts of activity often characterize periods
of enhanced neuropeptide release. For example, during suckling
in the lactating rat and in pregnant animals OT magnocellular
neurons discharge synchronously to release large amounts of OT
into the systemic circulation which is dependent on dendritic OT
release [196,204], and VP magnocellular cells increase their ﬁring
(and may switch to phasic activity) to release VP following
dehydration [185,337] and hemorrhage [338].
The effects of GPCR ligands on PVN and SON neuronal function
can be direct or indirect depending upon whether they are admin-
istered peripherally, centrally via the circumventricular organs, or
intra-nuclei by injection or iontophoretic application. It should be
borne in mind that high doses of GPCR agonists may give ‘pharma-
cological’ rather than physiological responses, especially when
compounds are applied in the vicinity of their presumed site of
action. GPCR activation in the PVN/SON has been demonstrated
in a number of ways. These include increases in neuronal immedi-
ate early gene (e.g., c-fos) activation, changes in electrophysiologi-
cal characteristics or neuropeptide mRNA or protein levels (e.g., by
ISHH, ICH or content of push–pull perfusates or microdialysates),
and alterations in any number of physiological end-points such
as plasma VP, OT, CRF and ACTH release, water and energy homeo-
stasis, cardiovascular parameters, nociception and behavior (see
Supplementary Table 9 for some examples). The speciﬁcity of the
ligand–GPCR interaction is usually demonstrated by the inhibition
of responses with GPCR-selective antagonists or, as in a few cases,
by immunoneutralization with neuropeptide/GPCR antibodies
(e.g., for NPFF effects on VP release [364]), and more recently by
RNA interference-driven gene silencing that has the added advan-
tage over acute administration of synthetic small interfering RNAs
of long-term (days–months) GPCR knockdown if viral, GPCR-
speciﬁc small hairpin (sh)RNA constructs are employed. The
sustainable expression of such constructs obviates some of the
problems that may be encountered with long GPCR mRNA
turnover rates.
6.1. General features of GPCR function in the PVN and SON
With ampliﬁcation procedures used in various GPCR detection
techniques, an important question is what level of GPCR mRNA
or protein is physiologically relevant? Radioligand- or ﬂuores-
cent-ligand binding assays can detect as few as about 50–100
GPCRs per cell (e.g., see [212]) which is sufﬁcient to elicit (although
higher levels are probably required to sustain) a signal transduc-
tion response in some in vitro systems [297]. In PVN and SON neu-
rons in vivo some GPCRs may be clustered to concentrate their
levels at pre- or post-synaptic sites. A number of studies under-
score the differences in the sensitivity/speciﬁcity of detection tech-
niques used between laboratories, and highlight the importance of
obtaining (speciﬁc) functional GPCR responses. For example, while
VP V2 receptor mRNA was not detected in the PVN or SON by
nested PCR in one study [132], V2 receptor mRNA (by PCR on
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functional responses have recently been reported in isolated cells
from the SON [281]. Similarly, the lack of angiotensin II AT1A recep-
tor gene expression in the mPVN by ISHH in some studies (e.g.,
[186]) appears at odds with the AT1-type pharmacological re-
sponses observed by electrophysiology in PVN slices [176]. Fur-
thermore, prostanoid EP3 receptor electrophysiological responses
have been observed in the SON [290] where no ir-EP3 receptor cell
bodies or ﬁbers have been found [234].
It is possible that some of the GPCR effects in the PVN or SON
are spurious or redundant in nature, since it is difﬁcult to envisage
that every GPCR we have listed (see Tables 1 and 2) has an impor-
tant role in co-ordinating control of PVN and/or SON function. We
are reminded of a comment attributed to Alfred Gilman a number
of years ago: ‘‘A typical cell has perhaps 50 different receptors, and
the cell doesn’t pay attention to just one receptor at a time. How
does it know how to interpret the signal from one hormone when
it’s listening to 45 other ones at the same time? How does the
whole signaling system work as a network? That’s what we want
to ﬁnd out’’ [184]. Functional studies of GPCRs indicate that they
do have individual roles in the PVN and SON and are probably
key to neurones integrating multiple functions as outline below
(see Supplementary Table 9).
Change in the levels of intracellular signal transduction mole-
cules (see Section 4.1) and immediate early gene activation
[126,127] are frequently used as indices of neuronal activity in
the PVN and SON, and are particularly amenable to cell imaging
techniques. For example, agonist-induced increases in intracellular
Ca2+ or ERK activation have been shown for 5-HT1A [61], a1A-adre-
noceptor [301], dopamine D4 [23], melanocortin MC4 [277], puri-
nergic P2Y1 [302], OT [24,172,277], VIP/PACAP [66] and VP V1A
[104] receptors. These are often accompanied by increases in
PVN or SON c-fos expression, as demonstrated for many GPCRs
such as the 5-HT2A/2C [180], CRF1 [251], dopamine D4 [23], gluca-
gon GLP-1 [175], melanocortin MC4 [157], motilin [359], neuropep-
tide FF/neuropeptide AF NPFF1 [145], prolactin-releasing peptide
PRRP [218,362] and tachykinin NK3 [157] receptors. One of the
most extensively studied functional aspects of GPCRs in pPVN pre-
sympathetic and/or endocrine, mPVN and SON neurons, is their of-
ten profound affects on neuronal excitability, examples of which
are shown in Supplementary Table 9, and include presynaptic ef-
fects mediated via metabotropic glutamate receptors [28,29,284]
and endocannabinoids (acting through cannabinoid CB1 receptors)
[68,277] in the SON, and GABA release in presympathetic pPVN
neurons [49,188].
GPCR activation in the PVN/SON can alter neuropeptide or GPCR
gene synthesis (e.g., see [3,79,80,167,201,346]) and/or the release
of neurotransmitters/neuropeptides from dendrites and/or axon
terminals. Local dendritic release of neuropeptides acting in an
autocrine or paracrine fashion are likely to be important factors
in determining the sensitivity and plasticity of PVN and SON neu-
rons to their multitude of inputs [173,202,204,231]. Dendritic pep-
tides may also regulate local blood ﬂow [5] and have local (e.g., OT
is anxiolytic via the PVN OT receptor [333]) and distant effects on
behavior [204]. Examples of GPCRs that modulate neuropeptide re-
lease, typically performed in studies measuring VP and/or OT re-
lease from large magnocellular cells, rather than CRF release
from the smaller pPVN neurons, include the a1-adrenoceptors (in-
hibit intra-PVN hypoxia-induced CRF release [50]), apelin APJ (in-
creases ﬁring rate of VP neurons and VP dendritic release [327]),
histamine H1/2 (increases dendritic release of OT via stimulating
noradrenaline release [18]), melanocortin MC4 (increases Ca2+ in
OT neurons; stimulation of dendritic, and inhibition of terminal
OT release [204,276]), j opioid (locally released dynorphin inhibits
VP neurons and is essential for expression of VP neuron phasic
activity; inhibits VP terminal release [34,36]), VIP/PACAP (stimu-lates somatodendritic and terminal VP release [208,289]), VP V1A
(acting on autoreceptors to excite and inhibit quiescent and phasic
VP neurons, respectively [35,203,204]), and OT (stimulates den-
dritic OT release via OT receptor; inhibits OT neurons by increasing
endocannabionoid inhibition of glutamate release [204]) receptors.
The release of neurohypophysial hormones from posterior pitu-
itary nerve terminals, and CRF and other pPVN products from the
median eminence into the anterior pituitary portal circulation is
often reﬂected by increased circulating levels of VP and OT, ACTH
(due to the action of CRF, VP and other ACTH secretagogues) and
CORT, and thyroid hormones, and in changes in water homeostasis
(principally brought about by altered VP secretion) (Supplemen-
tary Table 9 gives some examples). GPCRs can also modulate auto-
nomic functions by activating secretory and non-secretory pPVN
neurons. For example, central or intra-PVN administration of a
number of GPCR ligands results in orexigenic (e.g., ghrelin [291],
galanin [171], and NPY agonists via Y1 and Y5 [151] receptors) or
anorexigenic (e.g., via CRF1 [117], melanocortin MC4 [94], neuro-
peptide S NPS [78], and neuromedin U [357] receptors) effects,
and alter cardiovascular parameters (e.g., angiotensin AT1 [13],
CRF2 [189], tachykinin NK3 [320], and urotensin II UT [342] recep-
tors), nociception (e.g., a-adrenoceptors [374]), body temperature
(e.g., acetylcholine muscarinic receptors [319]), and penile erection
(e.g., dopamine receptors [312]).
6.2. Possible GPCR co-expression in the PVN and SON
We do not know how many GPCRs are co-expressed in PVN/
SON neurons, and different complements of GPCRs may be
expressed in subsets of neurons such as magnocellular VP cells
with different basal electrical activity, magnocellular neurons with
different neuropeptidergic phenotypes, mPVN versus pPVN neu-
rons, or pPVN endocrine versus non-endocrine neurons. However,
extrapolating from the study on single warm-sensitive neurons
(transcriptomic analysis gave 168 non-olfactory GPCRs of which
27 are orphans [73]) suggests that the number of co-expressed
GPCRs is likely to be larger than the number of co-expressed neu-
ropeptides. At least 20 different neuropeptides are co-expressed in
magnocellular VP or OT neurons [39] but the extent of the total
overlap is unknown. The co-expression of GPCRs raises the ques-
tion of possible functional consequences of receptor oligomeriza-
tion in the PVN and SON. The formation of functional GABAB
receptors from two GABAB subunits is an example of GPCR hetero-
dimerization that we know occurs in the PVN and SON [373]. Of
the GPCRs listed in Supplementary Table 4, there is also a high de-
gree of colocalization of 5HT1A and 5HT2A in OT and CRF neurons in
the PVN where activation of one receptor subtype may induce the
desensitization of the other [370]. There are many examples of
apparent GPCR homodimerization and heterodimerization in the
literature [225], and a number of consequences of GPCR oligomer-
ization such as changes in receptor expression, compartmentaliza-
tion, recycling, turnover and degradation have been noted mainly
in in vitro studies [88,304]. Assuming that oligomerization is rela-
tively stable, co-expressed GPCRs may allow graded regulation of a
population of functionally equivalent neurons in the PVN and SON,
as receptor ratios and the levels of their corresponding ligands vary
as a function of the physiological and pharmacological state. This
could mean that with oligomerization between GPCRs of the same
subclass it is possible that the heterodimer acts as a ‘concentra-
tion-dependent switch’ where one GPCR is activated by low ago-
nist concentrations whereas the other is activated by higher
agonist concentrations. The signaling of one GPCR could be shut
down while the other is active, e.g., by internalization of the ‘inac-
tive’ GPCR (e.g., see co-expressed adenosine A1/2A receptors [55];
note that the four adenosine receptor subtypes are all possibly
expressed in the PVN (see Supplementary Table 4)). Moreover,
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to coupling to a new G protein to activate a new signaling pathway
(e.g., see co-expressed dopamine receptors [179]). To add to the
complexity, GPCRs may also physically associate with non-GPCRs
e.g., the dopamine D5 receptor and the GABAA c2 ligand-gated
ion channel subunit appear to complex leading to an attenuation
in D5 receptor-mediated cAMP accumulation and GABAA-mediated
current [198].
6.3. Possible function of orphan GPCRs
Some orphan GPCRs, or indeed some GPCRs with known endog-
enous ligands, may be constitutively active in the PVN and SON.
This is not as far-fetched as it may seem since constitutive activity
in GPCRs is a relatively well-known phenomenon that can be sig-
naling pathway-dependent, and can result from the overexpres-
sion of receptors in native tissue or heterologous systems, and/or
by changes in the DNA (introduced or somatic mutations) or RNA
(visa vi RNA editing as in the 5-HT2C receptor [213]) sequence of
GPCRs. For example, isoforms of the histamine H3 receptor are con-
stitutively active pre- and post-synaptically in native brain cortical
tissue [230], and in cell lines a1A- and a1B-adrenoceptors (which
can heterodimerize) [60], bradykinin B2 [261], ghrelin [129], mela-
nocortin MC4 [239] and neurotensin NTS2 [129] receptors exhibit
constitutive activity, and co-expression of the constitutively active
histamine H1 receptor with the 5-HT1B receptor confers constitu-
tive activity on the latter receptor [14]. All these GPCRs are
expressed in the PVN and SON. The orphan GPCRs GPR3, 6, 12,
20, 26 (present in SON by DNA microarrays), 39, 61 (present in
PVN and SON by DNA microarrays) and 78 also alter basal signal
transduction activity when expressed in vitro [129,148,321,329].
Although we may be able to predict changes in GPCR activity based
on altered GPCR sequences, the demonstration of constitutive
activity in the PVN and SON needs to be functionally-based. A com-
ponent of the high, basal [35S]GTPcS labeling in the rat PVN [1]
may reﬂect constitutive basal activity of known and/or orphan
GPCRs. Highly expressed, constitutively active GPCRs may account
in part for the molecular mechanisms regulating signal transduc-
tion effectors in PVN/SON neurons. Some of these molecules e.g.,
cAMP, Ca2+, have key roles in axonal growth of developing or
regenerating neurons (e.g., [226]). Constitutive activity may also
underlie ligand-independent functions of orphan GPCRs such as
involvement in GPCR heterodimerization and altering target GPCR
function – an example of this is the orphan GPCR GPR50 heterodi-
merizing with the melatonin MT1 receptor to inhibit its activity
(see [187]). In fact, constitutive activity is observed in the PVN
and SON. For example, nitric oxide whose generation is enhanced
by many GPCR agonists, and which has general inhibitory
neuroendocrine and autonomic effects in the PVN and SON [306],
constitutively restrains ongoing ﬁring in SON neurons [307]. As
to GPCR-‘speciﬁc’ effects, very recently the melanocortin MC4
receptor was shown to be constitutively active in the mouse PVN
[96].
There are a number of candidate substances that may be ligands
for orphan GPCRs expressed within the PVN and SON. These
include peptides that modulate PVN/SON function and/or are
perhaps expressed in mPVN and SON, or pPVN neurons. Various
peptides derived from larger precursor molecules (and isolated
by proteomic methods) are expressed in the PVN/SON, such as:
(1) the neuroendocrine regulatory peptides (NERPS-1/2), which
are products of the VGF gene that colocalize with VP in the storage
granules of the PVN and SON of both rats and humans, and sup-
press basal, hypertonic saline- or angiotensin II-induced VP release
[328,363]; (2) neuronostatin, a product of the somatostatin gene
that depolarizes or hyperpolarizes PVN magnocellular, parvocellu-
lar or preautonomic neurons and administered centrally increasesblood pressure and decreases food intake and water drinking
[279]; (3) nesfatin-1, an amino-terminal fragment derived from
NEFA/nucleobindin 2 (NUCB2) [93] that is present in VP and OT
neurons [30], elevates intracellular Ca2+ in dissociated hypotha-
lamic [30] and isolated PVN [211] neurons, alters the electrophys-
iological properties of PVN neurons [257], increases OT release
from PVN tissue slices [211] and administered centrally increases
c-fos in the PVN/SON and decreases food intake via an OT-depen-
dent, leptin-independent melanocortin pathway [211,93] (note
that it has been reported that nesfatin activates GPR12 [229], an
orphan GPCR which exhibits constitutive activity [321]); and (4)
augurin, a product of the c2orf40 gene which encodes the esopha-
geal cancer-related gene 4 (ECRG4) protein) [318] that is present in
PVN and SON OT and VP neurons [271], increases VP and CRF
release from hypothalamic explants and elevates plasma ACTH
levels when administered centrally or intra-PVN [318]. It is inter-
esting to note that peptidomics of the rat SON has identiﬁed 20
unique peptides from known pro-hormones [27]. Candidate
orphan GPCR ligands are not restricted to peptides and their
by-products and post-translationally modiﬁed counterparts, but
could also include compounds such as steroids (e.g., glucocorti-
coids) that are known to interact with the PVN/SON. There are a
number of ‘fast’, apparently non-genomic effects of steroids [199]
and their metabolites (e.g., see [236]) that may be mediated by
GPCRs, including chemosensory receptors, in the PVN/SON and
other brain regions. A comparison of brain region and peripheral
tissue localization and effects of candidate orphan GPCR ligands
with the anatomical distribution of orphan GPCR gene expression
could possibly contribute to GPCR ‘deorphanization’ in the PVN
and SON.7. Concluding remarks
The neuronal universe of GPCRs and associated signaling com-
ponents in the PVN and SON is expanding: removal of one constit-
uent may not upset the fabric of the system in its basal state (e.g.,
there is probably some redundancy in the system) but we can mea-
sure alterations in individual elements, and these may inﬂuence
the function of the system as a whole as it responds to different
stimuli. It is evident that GPCR gene expression and protein data,
preferably veriﬁed by at least two methods, needs to be comple-
mented with functional data. Single cell transcriptomic proﬁling
(including deep sequencing) will likely extend the number of
potentially functional GPCRs in PVN and SON neurons, but such
studies will possibly have to sample a number of different neuronal
populations to deal with the heterogenous nature of the cells.
These experiments can be performed on electrophysiologically-
identiﬁed neurons, or on cells that have been identiﬁed by
complementary techniques such as high-resolution 2-photon
Ca2+ imaging that has been extensively used in other brain regions
like the hippocampus (e.g., [258]). GPCRs are not abundant com-
pared to most cytoplasmic proteins, and are difﬁcult to analyze
by gel-based techniques such as 2D-difference gel electrophoresis
(DIGE) due to their inherent hydrophobicity and insolubility in
standard detergents. Global proteomic approaches to analyze GPCR
expression are still not within reach, currently requiring methods
such as selectively tagging (e.g., by biotinylation) cell surface
proteins, various chromatography techniques including immobi-
lized-metal afﬁnity chromatography (IMAC), or the isotope-coded
afﬁnity tag (ICAT) method prior to protein analysis by mass
spectrometry [344].
It is likely in the future that high-resolution RNA-[347] and pro-
tein-tracking methods will be used in conjunction with functional
imaging to study the consequences of spatial and temporal
changes in GPCR expression in the PVN, SON and elsewhere in
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although ﬂuorescent and biotinylated GPCR ligands have been
available since the 1970s, it is only fairly recently that improved
ﬂuorophores and conjugation methods with increased signal/noise
ratios and bioactivity have made these compounds viable alterna-
tives to radiolabeled compounds in viewing the native tissue
distributions of GPCRs. For example, while ﬂuorescent GPCR
ligands may not have been speciﬁcally applied to either PVN or
SON sections or viable tissue, they have been used to detect rela-
tively abundant GPCRs such as a-adrenoceptors in arteries and
dopamine receptor subtypes in brain [8,64]. We are in the midst
of an era where ﬂuorescent GPCR ligands can also potentially
be used to investigate GPCR internalization and ﬂuorescence
resonance energy transfer (FRET)- and bioluminescence energy
transfer (BRET)-based measurements to reveal oligomer formation
between homologous or heterologous GPCRs, or between other
proteins in single PVN/SON cells or within whole tissue [4].
Undoubtedly valuable physiological information will be ob-
tained by the continued use of murine (and perhaps future rat)
GPCR knockout models, even though there are ongoing concerns
over compensatory mechanisms possibly distorting phenotypes
in global knockouts, potentially different physiological phenotypes
(e.g., behavior) on different genetic backgrounds, and the different
PVN cytoarchitecture between rats and mice [352]. One mouse line
with conditional PVN transcriptional re-activation (i.e., functional
recovery) of a GPCR has been reported (melanocortin MC4 receptor
[15]) but to our knowledge no inducible (e.g., by drugs such as tet-
racyclin) PVN/SON GPCR knockouts are available. ‘Translational’
research dictates the importance of applying scientiﬁc discoveries
into practical applications like improving human health. Variations
in GPCR agonist levels or in GPCRs themselves, e.g., brought about
by exposure to stressors, is potentially relevant to a number of hu-
man conditions such as depression and cardiovascular disorders
where GPCR changes may promote pathological outcomes. Studies
on GPCRs in the human PVN and SON are relatively scarce and of-
ten fraught with over-interpretation when compared with rat
experiments, not least because the human PVN does not have the
clear anatomical demarcations as its rat equivalent [314]. Species
differences in brain GPCR distribution are also not uncommon
(and may partly underlie some behavioral phenotypes [367]),
advising caution in extrapolating data on GPCRs from animals to
humans. However, conservation of GPCR expression in the PVN/
SON between rodents and humans or non-human primates rein-
forces the idea that a particular GPCR may have an important func-
tional role. For example, the 5-HT1A/1C [252], b2-adrenoceptor
[197], dopamine D1/2/3/5 [108,270], neuropeptide Y5 [238] and
tachykinin NK3 [168] receptors are all present in the human PVN
and SON, while CRF1 and VP V1A receptor transcript levels appear
to be elevated in the PVN of depressed patients [340]. Other GPCRs
like the free fatty acid FFA1 [209] and melatonin MT1 [360] recep-
tors are present in the primate PVN and SON by IHC but to date
have not been shown in the same structures in the rat. A number
of studies in humans are compatible with those in rats suggesting
GPCR action in the PVN. For example, peripheral melatonin modu-
lates the VP response to exercise and hypertonic saline infusion
[86], while naloxone (a l-opioid receptor blocker) enhances the
plasma ACTH response to CRF [56]. In non-human primates, the
odd study has investigated the effects of intranasal [250] and
central [296] administration of GPCR ligands on PVN-based activ-
ity. Further exploration of GPCR expression and function in the
PVN and SON of humans and experimental animals, including cor-
relative studies on the possible impact of GPCR gene variations
(e.g., single nucleotide polymorphisms), will contribute signiﬁ-
cantly to unraveling the inﬂuence of GPCRs on the homeostatic
roles of the PVN and SON under normal conditions and in disease
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